Inventor · disambiguated record
Natarajan Sethuraman
Also filed as: SETHURAMAN NATARAJAN
15 granted patents·19 pending applications·84 citations·filing 1992–2024
92Inventor score
Files withENTRADA THERAPEUTICS INC9MERCK SHARP & DOHME8SETHURAMAN NATARAJAN4ME MEDICAL ENZYMES AG3UNIV SOUTH CAROLINA3
Top patents by PatentIndex Score
34 records- 0194US11987821B2Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyENTRADA THERAPEUTICS INC·Filed 2021·Granted May 21, 2024·2 cites·18 claims
- 0292US11168310B2Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyENTRADA THERAPEUTICS INC·Filed 2020·Granted Nov 9, 2021·6 cites·35 claims
- 0392US8067339B2Surface display of whole antibodies in eukaryotesPRINZ BIANKA·Filed 2009·Granted Nov 29, 2011·18 cites·11 claims
- 0490US8715963B2Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastorisSETHURAMAN NATARAJAN·Filed 2011·Granted May 6, 2014·16 cites·18 claims
- 0582US9260712B2Surface display of whole antibodies in eukaryotesPRINZ BIANKA·Filed 2011·Granted Feb 16, 2016·3 cites·18 claims
- 0682US2025115885A1Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathyENTRADA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0779US9428784B2Methods for increasing N-glycan occupancy and reducing production of hybrid N-glycans in pichia pastoris strains lacking ALG3 expressionMERCK SHARP & DOHME·Filed 2012·Granted Aug 30, 2016·4 cites·14 claims
- 0878US9139632B2Method for producing proteins in Pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigensBOBROWICZ PIOTR·Filed 2010·Granted Sep 22, 2015·5 cites·10 claims
- 0977US12084651B2Surface display of whole antibodies in eukaryotesMERCK SHARP & DOHME LLC·Filed 2021·Granted Sep 10, 2024·0 cites·11 claims
- 1075US7851438B2Erythropoietin compositionsGLYCOFI INC·Filed 2007·Granted Dec 14, 2010·1 cites·14 claims
- 1172US6939541B2Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyaseUNIV SOUTH CAROLINA·Filed 2001·Granted Sep 6, 2005·5 cites·21 claims
- 1270US7052689B2Method for producing therapeutically suitable glutaminaseME MEDICAL ENZYMES AG·Filed 2001·Granted May 30, 2006·3 cites·6 claims
- 1369US11046951B2Surface display of whole antibodies in eukaryotesMERCK SHARP & DOHME·Filed 2018·Granted Jun 29, 2021·0 cites·14 claims
- 1467US6312939B1Genetically engineered glutaminase and its use in antiviral and anticancer therapyME MEDICAL ENZYMES AG·Filed 1992·Granted Nov 6, 2001·21 cites·17 claims
- 1563US9758553B2Yeast strain for the production of proteins with terminal alpha-1,3-linked galactoseMERCK SHARP & DOHME·Filed 2014·Granted Sep 12, 2017·0 cites·6 claims
- 1663US2017327817A9Surface display of whole antibodies in eukaryotesMERCK SHARP & DOHME·Filed 2016·Application pending·0 cites
- 1761US2024417429A1Compositions and methods for skipping exon 45 in duchenne muscular dystrophyENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1860US2011086054A1Yeast strain for the production of proteins with terminal alpha-1,3-linked galactoseSETHURAMAN NATARAJAN·Filed 2009·Application pending·0 cites
- 1958US2025051393A1Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activityENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2058US2023027739A1Antigen-binding and antigen degradation constructsENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2157US2025051780A1COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICINGENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2255US2014227290A1Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastorisMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 2355US2008145354A1Pegylation of therapeutic agentsUNIV SOUTH CAROLINA·Filed 2008·Application pending·0 cites
- 2455US2024247259A1Compositions and methods for modulating gene expressionENTRADA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2554US2006240414A1Genetically engineered glutaminase and its use in antiviral and anticancer therapyME MEDICAL ENZYMES AG·Filed 2006·Application pending·0 cites
- 2651US8137954B2Erythropoietin compositionsSETHURAMAN NATARAJAN·Filed 2010·Granted Mar 20, 2012·0 cites·10 claims
- 2749US2023020092A1Compositions for delivery of antisense compoundsENTRADA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2849US2006034817A1Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyaseUNIV SOUTH CAROLINA·Filed 2005·Application pending·0 cites
- 2948US2016215061A1Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIBMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 3048US2006276438A1Prevention and treatment of influenza with glutamine antagonist agentsSETHURAMAN NATARAJAN·Filed 2005·Application pending·0 cites
- 3144US2014342932A1Functional cell surface display of ligands for the insulin and/or insulin growth factor 1 receptor and applications thereofMERCK SHARP & DOHME·Filed 2012·Application pending·0 cites
- 3244US2002065397A1Protecting therapeutic compositions from host-mediated inactivationFiled 2001·Application pending·0 cites
- 3344US2016289290A1N-glycosylated insulin analoguesMERCK SHARP & DOHME·Filed 2016·Application pending·0 cites
- 3437US2014235537A1N-glycosylated insulin analoguesMEEHL MICHAEL·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Natarajan Sethuraman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →